

(51) International Patent Classification:
C07D 285/08 (2006.01)(21) International Application Number:
PCT/GB2010/001315(22) International Filing Date:
8 July 2010 (08.07.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/213,735 8 July 2009 (08.07.2009) US(71) Applicant (for all designated States except US): **BE-TAGENON AB** [SE/SE]; Box 2339, S-103 18 Stockholm (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **WESTMAN, Jacob** [SE/SE]; Medchemcon AB, Blomsberg, S-740 21 Järläsa (SE). **HALLETT, Allan** [GB/GB]; Antisoma Research Limited, BioPark Hertfordshire, Broadwater Road, Welwyn Garden City, Hertfordshire AL7 3AX (GB). **VAGBERG, Jan** [SE/SE]; Brantstigen 8, S-192 54 Solentuna (SE).(74) Agent: **McNeeney, Stephen**; Potter Clarkson LLP, Park View House, 58 The Ropewalk, Nottingham NG1 5DD (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report (Rule 48.2(g))

(54) Title: COMPOUNDS USEFUL AS MEDICAMENTS

Dephosphorylation assay Ex 1 vs. Ex 2c





Figure 3

n=4



(I)

(57) Abstract: According to the invention there is provided a compound of formula (I), wherein, X, W, A₁ to A₅ and D have meanings given in the description, which compounds are useful in the treatment of cancer.